Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
MiNK Therepeutics
|
2024 | |||
Mink Therapeutics Q1 2024 |
Mink Therapeutics Q2 2024 |
||
May 14, 2024 | Aug. 13, 2024 | ||
2023 | |||
Mink Therapeutics Q1 2023 |
Mink Therapeutics Q2 2023 |
Mink Therapeutics Q3 2023 |
Mink Therapeutics Q4 2023 |
May 11, 2023 | Aug. 10, 2023 | Nov. 9, 2023 | Mar. 21, 2024 |
2022 | |||
Mink Therapeutics Q1 2022 Press Release |
Mink Therapeutics Q2 2022 |
Mink Therapeutics Q3 2022 |
Mink Therapeutics Q4 2022 |
May 10, 2022 | Aug. 9, 2022 | Nov. 3, 2022 | March 21, 2023 |
MiNK Therapeutics (INKT) is a clinical-stage biotechnology company specializing in cell therapies for cancers and immunological diseases.
Note: Agenus (AGEN) owns a majority of the shares of INKT common stock, per 2021 10-K
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CDTX |
CLDX |
FATE |
GILD |
GLYC |
ILMN |
INCY |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
SYRS |
TSVT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers